ALK-Abelló A/S

About ALK-Abelló A/S

ALK-Abelló A/S is a global leader in allergy immunotherapy, dedicated to improving the lives of individuals suffering from allergic conditions. Founded in 1923, the company has a rich history of innovation and commitment to research and development in the field of allergy treatment.

With a strong focus on patient-centric solutions, ALK-Abelló offers a wide range of products, including sublingual and injectable immunotherapy treatments. These therapies are designed to provide long-term relief from allergy symptoms and address the underlying causes of allergies.

The company operates in over 30 countries, with a significant presence in Europe and North America. ALK-Abelló’s state-of-the-art manufacturing facilities adhere to the highest quality standards, ensuring the safety and efficacy of its products.

In addition to its product offerings, ALK-Abelló invests heavily in clinical research to advance the understanding of allergies and develop new treatment options. The company’s commitment to education and awareness is evident through its various initiatives aimed at healthcare professionals and patients alike.

ALK-Abelló is driven by a vision to create a world where allergy sufferers can lead normal lives without the burden of their conditions. The company values collaboration and partnerships with healthcare providers, researchers, and patient organizations to achieve this goal.

As a socially responsible organization, ALK-Abelló is committed to sustainability and ethical practices in all aspects of its operations. The company strives to minimize its environmental impact while delivering high-quality healthcare solutions.

In summary, ALK-Abelló A/S stands at the forefront of allergy treatment, combining scientific expertise with a passion for improving patient outcomes. Through continuous innovation and dedication to excellence, ALK-Abelló aims to transform the landscape of allergy care worldwide.